AirNexis Therapeutics, Inc.
Explore the future of inhaled therapy for COPD with AirNexis's innovative AN01 dry powder inhaler designed for ease of use.
1 additional officer or director
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- $62Msold on Form D
Filed a Form D on 9 Jan 2026: $62M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.
A company that just raised has fresh capital, a new board and new vendors to choose.
- 2 investorsnamed
2 investors on record.
The investors already on the cap table shape who leads the next round.
- 4 directorsboard
4 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
Financing history
- Jan 9, 2026Form D equity offering · $62.0M (form d sold) · 13 investorsFact Form D · “AirNexis Therapeutics, Inc. filed Form D: $62,000,000 sold of $200,000,000, Biotechnology”
Investors on record
- Frazier Life Sciences Management, LP portfolio listing Fact frazierls.com
- LSP Or Life Sciences Partners portfolio listing Fact airnexis.com
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.
Evidence: 1 listingeach firm's own card, as read
- Status not stated on Frazier Life Sciences Management, LP · the firm's card prints no outcome · read Oct 1, 2026 frazierls.com“Airnexis Therapeutics”
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- James Li Executive Officer/Director sec.gov
- Maria Fardis Executive Officer/Director sec.gov
- Anna Chen Director Fact
- Jill Carroll Director Fact
- Colin Walsh Director Fact
Timeline
- Mar 9, 2026AirNexis Therapeutics, Inc. filed Form D: $62,000,000 sold of $200,000,000, BiotechnologyForm D filed Fact Form D
Evidence
Every observation on this company
- Description: Oct 1, 2026 Fact
- Entity type: Corporation Mar 9, 2026 Fact Form D
- Form D industry group: Biotechnology Mar 9, 2026 Fact Form D
- Amendment: false Mar 9, 2026 Fact Form D
- Revenue range (Form D): Decline to Disclose Mar 9, 2026 Fact Form D
- Incorporated: withinFiveYears Mar 9, 2026 Fact Form D
- Investors named on site: 1 Oct 1, 2026 Fact
- Jurisdiction: Delaware Mar 9, 2026 Fact Form D
- Amount sold (Form D): $62.0M Mar 9, 2026 Fact Form D
- Offering amount (Form D): $200M Mar 9, 2026 Fact Form D
- Exemptions: 06b Mar 9, 2026 Fact Form D
- First sale: 2026-01-09 Mar 9, 2026 Fact Form D
- Investors (Form D): 13 Mar 9, 2026 Fact Form D
- Minimum investment (Form D): 0 Mar 9, 2026 Fact Form D
- Securities offered: equity Mar 9, 2026 Fact Form D
- Office address: Mar 9, 2026 Fact Form D
- Listed on portfolio page: Frazier Life Sciences Management, LP Oct 1, 2026 Fact Firm website
- Website status: ok Oct 1, 2026 Fact
- Site title: Oct 1, 2026 Fact
- Year of incorporation: 2024 Mar 9, 2026 Fact Form D
Relationships across DFX
on 1 other DFX graph
AirNexis Therapeutics, Inc. is the same institution as 1 record in Private Equity.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…
Record history
- Form D filed2026-03-09source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.